26 Jul 2017 --- In the first half of 2017, Lonza continued on its strong growth path, with sales up 15.1 percent to CHF2.323 million (US$2.43 million) and CORE EBIT up 43.3 percent to CHF447 million in reported currency compared with financial results in Half-Year 2016. The success was driven by both the Pharma&Biotech and Specialty Ingredients segments. Consumer Health & Nutrition outperformed others within Specialty Ingredients, and other businesses improved profitability, too. Therefore, Lonza confirms its full-year 2017 guidance on a standalone basis, which was already upgraded with the Q1 2017 Qualitative Business Update in April 2017.
